Iqvia reports Q1 adjusted EPS $2.70, consensus $2.63

Reports Q1 revenue $3.83B, consensus $3.77B. “IQVIA (IQV) delivered strong revenue and profit performance, at the high-end of our expectations,” said Ari Bousbib, chairman and CEO of IQVIA. “In the clinical trial business, we experienced delayed decision-making by customers on new programs, reflecting incremental macroeconomic and industry sector uncertainty. Despite the environment, our R&DS forward-looking indicators such as qualified pipeline, RFP flow, and backlog continued to grow. On the commercial side, the TAS business delivered above target performance, with revenue growth of 7.6 percent at constant currency. Our strong financial results demonstrate that we are navigating the current market conditions more effectively than our sector, reflecting the scale and strength of our differentiated portfolio and the resilience of our operational execution.”